The maker of the EpiPen kept repeating one stat to Congress, and it's total nonsense

The CEO of Mylan, the company that makes EpiPens, appeared before
Congress on Wednesday to explain why her company raised the price
of the lifesaving allergy drug by 500%, causing public outrage.

She was less than effective, to say the least.

One of the points the CEO, Heather Bresch, made over and over in
her defense was that Mylan had saved the American people $180
billion on drugs. She didn't explain how.

But Bresch did use that figure to justify her 617% compensation
increase. Bresch, who started out at Mylan as an executive
assistant, made $18 million in 2015.

Anyway, back to that $180 billion number. It's pretty big, so we
had to ask Mylan how it calculated it. Here's the company's
response:

"According to the Generic Pharmaceutical Association's
2015 Generic Drug Savings in the U.S. report, from 2005 to
2014 generic drugs saved the U.S. healthcare system $1.68
trillion. During this time period, Mylan's average market share
of the generics market was about 11%, which equates to Mylan
delivering approximately $180 billion in savings to the US
healthcare system."

So let me get this straight, Mylan. You're saying that over a
nine-year period, your company saved the country $180 billion by
simply being in the generics business?

If that's the case, we're not talking heroism here. We're not
talking big discounts or any kind of major sacrifice or goodwill
from the company — we're talking about the company literally just
performing its function. The inherent nature of a generic drug is
to cost less than a branded drug.

This is like Toyota saying Camrys save the US money because
Americans could've been buying Ferraris.

Bresch didn't specify in her testimony that she was talking about
generics or that she was talking about a specific time period.
She just threw that number out there into the wind with no
context.

And the thing is, whatever we're saving on generics doesn't seem
to be enough anyway. Health-insurance premiums are increasing in
the US in part because the cost of drugs is so high.

"One explanation for this is that increasing drug prices and
costs from medical suppliers have gotten so bad that employers
finally decided to share the price hikes with workers.
Additionally, there is some
evidence that people tend to be more cautious with their
healthcare spending in general when they have a high-deductible
plan, even for nondeductible costs, so employers are trying to
slow the total spending."

In short, the question shouldn't be how much we're saving on
generic drugs; it should be why aren't we saving enough to keep
costs from exploding? Apparently that $180 billion effort from
Mylan is not up to the task.

The EpiPen, by the way, is a branded product, so it had no hand
in Mylan's "savings to the US healthcare system." It also makes
up just under 10% of the company's revenue, according to Bresch's
testimony. Of course, she didn't bring exact figures with her as
Congress requested, so that's just a ballpark figure.